In this meta-analysis of randomized controlled trials (RCTs) including 31,397 participants globally, colchicine significantly reduced the incidence of major adverse cardiovascular events in both acute atherothrombotic and all cardiovascular disease across multiple ethnicities.

Cumulative-dose analyses showed a threshold protective effect of colchicine, clinically corresponding to treatment with 0.5 mg daily for at least 6 months. There was no signal of increased all-cause or non-cardiovascular mortality.

This study provides novel data that substantiate current clinical guideline recommendations.